GlassScriptPhysician profile
Deborah A Tyson
NPI 1164980017
$4,254.38
in general payments reported to CMS, 2019-2025
19 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $450 · 2022: $212 · 2023: $708 · 2024: $1,755 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.60 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.58 | 2021-2025 | |
| Alkermes, INC. | $702.71 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $700.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $340.80 | 2021-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $316.69 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $299.14 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $274.10 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $248.28 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $122.04 | 2021-2022 | |
| Corium, LLC | $108.84 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $69.40 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $64.59 | 2021-2024 | Ingrezza |
| Bioxcel Therapeutics, INC. | $46.54 | 2023 | Igalmi |
| Almatica Pharma LLC | $43.63 | 2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $35.59 | 2024-2025 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.81 | 2021 | |
| Indivior INC. | $18.41 | 2023 | Perseris |
| Collegium Pharmaceutical, INC. | $13.59 | 2025 | Jornay Pm |
| Allergan, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.